• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/12/21 5:25:51 PM ET
    $MTCR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MTCR alert in real time by email
    SC 13G 1 d103825dsc13g.htm SC 13G SC 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Schedule 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED

    PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO 13d-2 (b)

    (Amendment No. )

     

     

    Metacrine, Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    59101E 10 3

    (CUSIP Number)

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    (Continued on following pages)


    CUSIP #59101E 10 3  

     

      1    

    NAME OF REPORTING PERSONS

     

    Polaris Partners VII, L.P.

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐        (b)  ☒

     

      3  

    SEC USE ONLY

     

      4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

    SOLE VOTING POWER

     

    0

       6   

    SHARED VOTING POWER

     

    2,715,316 (1)

       7   

    SOLE DISPOSITIVE POWER

     

    0

       8   

    SHARED DISPOSITIVE POWER

     

    2,715,316 (1)

      9    

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,715,316 (1)

    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    10.5% (2)

    12  

    TYPE OF REPORTING PERSON

     

    PN

     

    (1)

    All such shares are held of record by PP VII (as defined in Item 2(A) below). PMC VII (as defined in Item 2(A) below), the general partner of PP VII, may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Amir Nashat, a member of the Issuer’s board of directors, and Bryce Youngren are the managing members of PMC VII and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 25,956,300 shares of Common Stock outstanding as of November 9, 2020, as reported on the Issuer’s Quarterly Report on Form 10-Q, for the quarter ended September 30, 2020, as filed with the United States Securities and Exchange Commission on November 12, 2020 (the “Form 10-Q”).


    CUSIP #59101E 10 3  

     

      1    

    NAME OF REPORTING PERSONS

     

    Polaris Entrepreneurs’ Fund VII, L.P.

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐        (b)  ☒

     

      3  

    SEC USE ONLY

     

      4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

    SOLE VOTING POWER

     

    0

       6   

    SHARED VOTING POWER

     

    178,942 (1)

       7   

    SOLE DISPOSITIVE POWER

     

    0

       8   

    SHARED DISPOSITIVE POWER

     

    178,942 (1)

      9    

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    178,942 (1)

    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0.7% (2)

    12  

    TYPE OF REPORTING PERSON

     

    PN

     

    (1)

    All such are held of record by PEF VII (as defined in Item 2(a) below). PMC VII, the general partner of PEF VII, may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Amir Nashat, a member of the Issuer’s board of directors, and Bryce Youngren are the managing members of PMC VII and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 25,956,300 shares of Common Stock outstanding as of November 9, 2020, as reported on the Issuer’s Form 10-Q.


    CUSIP #59101E 10 3  

     

      1    

    NAME OF REPORTING PERSONS

     

    Polaris Management Co. VII, L.L.C.

      2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)  ☐        (b)  ☒

     

      3  

    SEC USE ONLY

     

      4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5     

    SOLE VOTING POWER

     

    0

       6   

    SHARED VOTING POWER

     

    2,894,258 (1)

       7   

    SOLE DISPOSITIVE POWER

     

    0

       8   

    SHARED DISPOSITIVE POWER

     

    2,894,258 (1)

      9    

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,894,258 (1)

    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ☐

    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    11.2% (2)

    12  

    TYPE OF REPORTING PERSON

     

    OO

     

    (1)

    2,715,316 of such shares are held of record by PP VII and 178,942 of such shares are held of record by PEF VII. PMC VII, the general partner of each of PP VII and PEF VII, may be deemed to have voting, investment and dispositive power with respect to these securities. David Barrett, Brian Chee, Amir Nashat, a member of the Issuer’s board of directors, and Bryce Youngren are the managing members of PMC VII and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 25,956,300 shares of Common Stock outstanding as of November 9, 2020, as reported on the Issuer’s Form 10-Q.


    CUSIP #59101E 10 3    SCHEDULE 13G   

     

    ITEM 1(A).

    NAME OF ISSUER

    Metacrine, Inc. (the “Issuer”)

     

    ITEM 1(B).

    ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES

    3985 Sorrento Valley Blvd., Suite C

    San Diego, CA 92121

     

    ITEM 2(A).

    NAME OF PERSONS FILING

    This Schedule 13G is being filed on behalf of each of the following persons: Polaris Partners VII, L.P. (“PP VII”), Polaris Entrepreneurs’ Fund VII, L.P. (“PEF VII”) and Polaris Management Co. VII, L.L.C. (“PMC VII” and together with PP VII and PEF VII, the “Reporting Entities”). David Barrett, Brian Chee, Amir Nashat, a member of the Issuer’s board of directors, and Bryce Youngren are the managing members of PMC VII. To the extent feasible, PEF VII invests alongside PP VII. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

     

    ITEM 2(B).

    ADDRESS OR PRINCIPAL OFFICE

    The address for each of the Reporting Entities:

    c/o Polaris Partners

    One Marina Park Drive, 10th Floor

    Boston, MA 02210

     

    ITEM 2(C).

    CITIZENSHIP

    PP VII and PEF VII are limited partnerships organized under the laws of the State of Delaware. PMC VII is a limited liability company organized under the laws of the State of Delaware.

     

    ITEM 2(D).

    TITLE OF CLASS OF SECURITIES

    Common Stock, par value $0.0001 per share

     

    ITEM 2(E)

    CUSIP NUMBER

    59101E 10 3

     

    ITEM 3.

    IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B), OR 13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

    Not applicable.

     

    ITEM 4.

    OWNERSHIP

    The following information with respect to the ownership of the common stock of the Issuer by the Reporting Entities filing this Statement is provided as of December 31, 2020:

    (a) Amount beneficially owned:

    See Row 9 of cover page for each Reporting Person and the corresponding footnotes.*

    (b) Percent of Class:

    See Row 11 of cover page for each Reporting Person and the corresponding footnotes.*

    (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote:

    See Row 5 of cover page for each Reporting Person and the corresponding footnotes.*


    (ii) Shared power to vote or to direct the vote:

    See Row 6 of cover page for each Reporting Person and the corresponding footnotes.*

    (iii) Sole power to dispose or to direct the disposition of:

    See Row 7 of cover page for each Reporting Person and the corresponding footnotes.*

    (iv) Shared power to dispose or to direct the disposition of:

    See Row 8 of cover page for each Reporting Person and the corresponding footnotes.*

     

    *

    Each of the Reporting Persons disclaims beneficial ownership as to such securities, except to the extent of his, her or its pecuniary interest therein.

     

    ITEM 5.

    OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

    Not applicable.

     

    ITEM 6.

    OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

    Under certain circumstances set forth in the limited partnership agreements of each PP VII and PEF VII, and the limited liability company agreement of PMC VII, the general and limited partners or members of each such entity, as applicable, may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the issuer owned by each such entity of which they are a partner or member, as applicable.

     

    ITEM 7.

    IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

    Not applicable.

     

    ITEM 8.

    IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

    See Exhibit A.

     

    ITEM 9.

    NOTICE OF DISSOLUTION OF GROUP.

    Not applicable

     

    ITEM 10.

    CERTIFICATION.

    Not applicable

    Material to be Filed as Exhibits.

    Exhibit A – Agreement regarding filing of joint Schedule 13G.


    CUSIP #59101E 10 3

     

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 12, 2021

     

    POLARIS PARTNERS VII, L.P.
    By:   Polaris Management Co. VII, L.L.C.
    By:  

    *        

      Authorized Signatory
    POLARIS ENTREPRENEURS’ FUND VII, L.P.
    By:   Polaris Management Co. VII, L.L.C.
    By:  

    *        

      Authorized Signatory
    POLARIS MANAGEMENT CO. VII, L.L.C.
    By:  

    *        

      Authorized Signatory

     

    *By:  

    /s/ Lauren Crockett

    Name:   Lauren Crockett
      Attorney-in-Fact

    [*This Schedule 13G was executed pursuant to a Power of Attorney. Note that copies of the applicable Powers of Attorney are already on file with the appropriate agencies.]

    Get the next $MTCR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MTCR

    DatePrice TargetRatingAnalyst
    10/22/2021$2.50Outperform → Sector Perform
    RBC Capital Mkts
    10/22/2021$19.00 → $1.00Buy → Hold
    Canaccord Genuity
    10/22/2021$14.00 → $2.00Buy → Hold
    Jefferies
    10/22/2021Buy → Neutral
    HC Wainwright & Co.
    More analyst ratings

    $MTCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Klassen Preston

      4 - Metacrine, Inc. (0001634379) (Issuer)

      3/24/23 12:35:32 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4: York Michael sold $44,331 worth of shares (107,054 units at $0.41), decreasing direct ownership by 51% to 103,499 units (tax withholding)

      4 - Metacrine, Inc. (0001634379) (Issuer)

      1/27/23 4:44:04 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4: Klassen Preston sold $157,266 worth of shares (380,605 units at $0.41), decreasing direct ownership by 41% to 541,905 units (tax withholding)

      4 - Metacrine, Inc. (0001634379) (Issuer)

      1/27/23 4:42:52 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Metacrine downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Metacrine from Outperform to Sector Perform and set a new price target of $2.50

      10/22/21 7:43:25 AM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Metacrine downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Metacrine from Buy to Hold and set a new price target of $1.00 from $19.00 previously

      10/22/21 7:42:38 AM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Metacrine downgraded by Jefferies with a new price target

      Jefferies downgraded Metacrine from Buy to Hold and set a new price target of $2.00 from $14.00 previously

      10/22/21 7:42:07 AM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTCR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Metacrine and Equillium Mutually Agree to Terminate Definitive Merger Agreement

      LA JOLLA, Calif., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR) and Equillium, Inc. today announced the mutual termination of their previously announced definitive merger agreement. Metacrine is continuing to evaluate all strategic opportunities. Additional information regarding the termination of the definitive merger agreement is provided set forth in a Current Report on Form 8-K filed by Metacrine with the U.S. Securities and Exchange Commission today and is available at www.sec.gov and on Metacrine's website under the heading "Investors." About Metacrine Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies t

      12/23/22 4:01:00 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Metacrine Reports Third-Quarter 2022 Results

      SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal diseases, today reported its third-quarter 2022 financial results. "We made great progress during the quarter in advancing our proposed merger with Equillium," said Preston Klassen, M.D., MHS, president and chief executive officer of Metacrine. "We believe that Equillium has demonstrated compelling clinical data in Lupus Nephritis and has an exciting pipeline of clinical programs with multiple upcoming data catalysts and potential value inflection events. Equillium is led by an accomplished leadership

      11/14/22 4:38:48 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Equillium to Acquire Metacrine in All-Stock Transaction

      Expected to add $33 million in cash at closing to Equillium's balance sheet and extend operating runway into 2024 Acquisition includes novel drug candidate MET642, an orally delivered Phase 2 ready FXR agonist for ulcerative colitis Preston Klassen, M.D., MHS, to be appointed to the Board of Directors Equillium, Inc. (NASDAQ:EQ) and Metacrine Inc. (NASDAQ:MTCR), today announced that the two companies have entered into a definitive merger agreement pursuant to which Equillium will acquire Metacrine in an all-stock transaction. The transaction is anticipated to add $33 million in cash to Equillium's balance sheet at closing, which is expected to extend the company's cash runway into 2024.

      9/6/22 4:00:00 PM ET
      $EQ
      $MTCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products

    $MTCR
    SEC Filings

    See more
    • SEC Form 15-12G filed by Metacrine Inc.

      15-12G - Metacrine, Inc. (0001634379) (Filer)

      3/24/23 5:29:55 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Metacrine Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - Metacrine, Inc. (0001634379) (Filer)

      3/24/23 5:28:02 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form S-8 POS filed by Metacrine Inc.

      S-8 POS - Metacrine, Inc. (0001634379) (Filer)

      3/23/23 4:34:58 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTCR
    Financials

    Live finance-specific insights

    See more
    • Equillium to Acquire Metacrine in All-Stock Transaction

      Expected to add $33 million in cash at closing to Equillium's balance sheet and extend operating runway into 2024 Acquisition includes novel drug candidate MET642, an orally delivered Phase 2 ready FXR agonist for ulcerative colitis Preston Klassen, M.D., MHS, to be appointed to the Board of Directors Equillium, Inc. (NASDAQ:EQ) and Metacrine Inc. (NASDAQ:MTCR), today announced that the two companies have entered into a definitive merger agreement pursuant to which Equillium will acquire Metacrine in an all-stock transaction. The transaction is anticipated to add $33 million in cash to Equillium's balance sheet at closing, which is expected to extend the company's cash runway into 2024.

      9/6/22 4:00:00 PM ET
      $EQ
      $MTCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products

    $MTCR
    Leadership Updates

    Live Leadership Updates

    See more
    • Metacrine Announces Resignation of Chief Medical Officer

      SAN DIEGO, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today announced that Hubert C. Chen, M.D., chief medical officer, has resigned to pursue a new opportunity. Dr. Chen's resignation is effective December 31, 2021. Preston Klassen, M.D., MHS, chief executive officer, is expected to assume responsibility for Metacrine's ongoing clinical trials and future clinical operations. "We appreciate Hubert's significant contributions during the last three years as we moved our pipeline through several important milestones," said Preston Klass

      12/27/21 8:00:00 AM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • Metacrine Appoints Dr. Julia C. Owens to Its Board of Directors

      SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced the appointment of Julia C. Owens, Ph.D. to the Company’s board of directors, effective April 1, 2021. Dr. Owens will serve as a member of the Compensation Committee.   “We’re excited to welcome Julia as a new independent director,” commented Richard Heyman, Ph.D., Metacrine’s chairman. “She is an accomplished biopharmaceutical executive, with an established track record in building companies, business development, capital formation and strategic partnerships. Juli

      4/5/21 4:05:00 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Metacrine Inc. (Amendment)

      SC 13G/A - Metacrine, Inc. (0001634379) (Subject)

      2/14/23 4:00:28 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Metacrine Inc. (Amendment)

      SC 13G/A - Metacrine, Inc. (0001634379) (Subject)

      2/8/23 3:43:35 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Metacrine Inc.

      SC 13G - Metacrine, Inc. (0001634379) (Subject)

      12/19/22 4:00:11 PM ET
      $MTCR
      Medicinal Chemicals and Botanical Products
      Health Care